INNV Logo

Innovus Pharmaceuticals, Inc. (INNV) Stock Forecast & Price Prediction

Live INNV Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Medical Care Facilities

$3.39

-0.07 (-2.02%)

12 Month Price Forecast For INNV

$3.39
Current Price
$467.94M
Market Cap
4 Ratings
Buy 0
Hold 3
Sell 1
Wall St Analyst Ratings

Distance to INNV Price Forecasts

+62.2%
To High Target of $5.50
+54.9%
To Median Target of $5.25
+47.5%
To Low Target of $5.00

INNV Price Momentum

+3.0%
1 Week Change
-10.1%
1 Month Change
-40.3%
1 Year Change
-13.7%
Year-to-Date Change
-49.3%
From 52W High of $6.69
+8.8%
From 52W Low of $3.12

๐Ÿค” Considering Innovus (INNV)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 4:26 PM UTC

INNV Analyst Ratings & Price Targets

Based on our analysis of 9 Wall Street analysts, INNV has a neutral consensus with a median price target of $5.25 (ranging from $5.00 to $5.50). The overall analyst rating is Hold (5.5/10). Currently trading at $3.39, the median forecast implies a 54.9% upside. This outlook is supported by 0 Buy, 3 Hold, and 1 Sell ratings.

Conversely, the most conservative target is provided by Lisa Gill at JP Morgan, suggesting a 47.5% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

INNV Analyst Consensus

0
Buy
3
Hold
1
Sell

INNV Price Target Range

Low
$5.00
Average
$5.25
High
$5.50
Current: $3.39

Latest INNV Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for INNV.

Date Firm Analyst Rating Change Price Target
Dec 17, 2024 JP Morgan Lisa Gill Underweight Downgrade $5.00
Oct 11, 2024 Keybanc Matthew Gillmor Sector Weight Initiates $0.00
Mar 13, 2024 JP Morgan Lisa Gill Neutral Maintains $6.00
Feb 8, 2024 Goldman Sachs Jamie Perse Neutral Maintains $7.00
Feb 15, 2023 Goldman Sachs Jamie Perse Neutral Maintains $9.00
Feb 8, 2023 JP Morgan Lisa Gill Neutral Maintains $8.00
Nov 23, 2022 Goldman Sachs Jamie Perse Neutral Maintains $8.00
Nov 16, 2022 Citigroup Jason Cassorla Neutral Maintains $8.00
Sep 15, 2022 Barclays Sarah James Equal-Weight Maintains $5.00
May 16, 2022 Baird Vikram Kesavabhotla Neutral Downgrade $5.00
May 11, 2022 Piper Sandler Jeff Garro Underweight Maintains $3.90
Apr 20, 2022 Piper Sandler Jeff Garro Underweight Downgrade $5.00
Dec 28, 2021 Goldman Sachs Jamie Perse Neutral Downgrade $4.00
Dec 27, 2021 Barclays Sarah James Equal-Weight Downgrade $6.50
Dec 17, 2021 JP Morgan Neutral Initiates $0.00
Sep 29, 2021 Citigroup Neutral Downgrade $0.00
Sep 22, 2021 William Blair Market Perform Downgrade $0.00
Sep 10, 2021 Cowen & Co. Market Perform Initiates $0.00
Aug 12, 2021 Barclays Steve Valiquette Overweight Upgrade $19.00
May 28, 2021 Baird Outperform Initiates $0.00

Stocks Similar to Innovus Pharmaceuticals, Inc.

The following stocks are similar to Innovus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Innovus Pharmaceuticals, Inc. (INNV) Financial Data

Innovus Pharmaceuticals, Inc. has a market capitalization of $467.94M with a P/E ratio of -21.2x. The company generates $806.61M in trailing twelve-month revenue with a -3.2% profit margin.

Revenue growth is +10.6% quarter-over-quarter, while maintaining an operating margin of -1.9% and return on equity of -9.5%.

Valuation Metrics

Market Cap $467.94M
Enterprise Value $507.53M
P/E Ratio -21.2x
PEG Ratio 42.4x
Price/Sales 0.6x

Growth & Margins

Revenue Growth (YoY) +10.6%
Gross Margin +17.7%
Operating Margin -1.9%
Net Margin -3.2%
EPS Growth +10.6%

Financial Health

Cash/Price Ratio +18.9%
Current Ratio 1.2x
Debt/Equity 38.3x
ROE -9.5%
ROA -2.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Innovus Pharmaceuticals, Inc. logo

Innovus Pharmaceuticals, Inc. (INNV) Company Overview

About Innovus Pharmaceuticals, Inc.

What They Do

Provides comprehensive care services for seniors.

Business Model

The company operates through the Program of All-Inclusive Care for the Elderly (PACE), which allows it to provide a range of medical and ancillary services to seniors. InnovAge generates revenue primarily through government reimbursements and payments for the services provided to its participants, ensuring they can live independently while receiving necessary care.

Additional Information

InnovAge serves participants across multiple states, including Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company has a strong focus on in-home care and offers various services such as primary care, therapy, and transportation, positioning itself as a comprehensive solution for elderly care. Founded in 2007 and headquartered in Denver, it rebranded from TCO Group Holdings, Inc. in January 2021.

Company Information

Sector

Healthcare

Industry

Medical Care Facilities

Employees

2,350

CEO

Mr. Patrick Blair

Country

United States

IPO Year

2020

Innovus Pharmaceuticals, Inc. (INNV) Latest News & Analysis

INNV stock latest news image
Quick Summary

InnovAge Holding Corp. will host its Q2 2025 earnings conference call on February 4, 2025, at 5:00 PM ET, featuring key executives and analysts from major financial firms.

Why It Matters

InnovAge's Q2 2025 earnings call indicates financial performance insights, potential growth opportunities, and market sentiment, influencing stock valuation and investment decisions.

Source: Seeking Alpha
Market Sentiment: Neutral
INNV stock latest news image
Quick Summary

InnovAge Holding Corp. reported its fiscal Q2 results for the period ending December 31, 2024, highlighting progress in business strength, top-line growth, and margin improvement.

Why It Matters

InnovAge's positive financial results indicate growth and improved margins, signaling potential for increased profitability and investment appeal in the healthcare sector for seniors.

Source: GlobeNewsWire
Market Sentiment: Neutral
INNV stock latest news image
Quick Summary

InnovAge Holding Corp. will release its fiscal Q2 2025 financial results on February 4, 2025, after market close, followed by a conference call at 5 p.m. that day.

Why It Matters

The upcoming earnings release and conference call for InnovAge may significantly impact stock performance, providing insights into financial health and future growth potential in the senior healthcare market.

Source: GlobeNewsWire
Market Sentiment: Neutral
INNV stock latest news image
Quick Summary

InnovAge Holding Corp. (NASDAQ: INNV) will discuss its Q1 2025 results in a conference call on November 5, 2024, at 5:00 PM ET with key executives participating.

Why It Matters

InnovAge's Q1 2025 earnings results can influence stock performance, investor sentiment, and analyst ratings. Key insights from executives can impact future growth expectations.

Source: Seeking Alpha
Market Sentiment: Neutral
INNV stock latest news image
Quick Summary

InnovAge Holding Corp. appointed Michael Scarbrough as President and COO, and Maria Lozzano as President of Pharmacy Services, effective November 4, 2024.

Why It Matters

Leadership changes at InnovAge may signal strategic shifts that could impact operational efficiency and growth, influencing investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
INNV stock latest news image
Quick Summary

InnovAge Holding Corp. reported its fiscal Q1 results for the period ending September 30, 2024, highlighting ongoing growth and improved margins in providing healthcare for seniors.

Why It Matters

InnovAge's strong fiscal first quarter results indicate effective strategy execution and margin improvement, signaling potential growth and stability, which can influence investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About INNV Stock

What is Innovus Pharmaceuticals, Inc.'s (INNV) stock forecast for 2025?

Based on our analysis of 9 Wall Street analysts, Innovus Pharmaceuticals, Inc. (INNV) has a median price target of $5.25. The highest price target is $5.50 and the lowest is $5.00.

Is INNV stock a good investment in 2025?

According to current analyst ratings, INNV has 0 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $3.39. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for INNV stock?

Wall Street analysts predict INNV stock could reach $5.25 in the next 12 months. This represents a 54.9% increase from the current price of $3.39. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Innovus Pharmaceuticals, Inc.'s business model?

The company operates through the Program of All-Inclusive Care for the Elderly (PACE), which allows it to provide a range of medical and ancillary services to seniors. InnovAge generates revenue primarily through government reimbursements and payments for the services provided to its participants, ensuring they can live independently while receiving necessary care.

What is the highest forecasted price for INNV Innovus Pharmaceuticals, Inc.?

The highest price target for INNV is $5.50 from at , which represents a 62.2% increase from the current price of $3.39.

What is the lowest forecasted price for INNV Innovus Pharmaceuticals, Inc.?

The lowest price target for INNV is $5.00 from Lisa Gill at JP Morgan, which represents a 47.5% increase from the current price of $3.39.

What is the overall INNV consensus from analysts for Innovus Pharmaceuticals, Inc.?

The overall analyst consensus for INNV is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $5.25.

How accurate are INNV stock price projections?

Stock price projections, including those for Innovus Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.